(Reuters) - Eli Lilly and Co on Wednesday said its drug Cyramza met the main goal of helping patients live longer in a late-stage trial, which tested it as a potential treatment for the most common type of liver cancer.
Original Article: Lilly's Cyramza succeeds in late-stage liver cancer trial